Nanoengineering approaches to the design of artificial antigen-presenting cells

Nanomedicine

Volumn 8, Issue 7, 2013, Pages 1173-1189

  Sunshine, Joel C ^a   Green, Jordan J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anisotropy; artificial antigen presenting cell; biomimetic; immunology; nanobiotechnology; nanoparticle; particle shape; polymer

Indexed keywords

CD1 ANTIGEN; CD3 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; LIPOSOME; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MEMBRANE PROTEIN; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ADHESION; CELL POPULATION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EX VIVO STUDY; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; MOLECULAR DYNAMICS; NANOENGINEERING; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 84879673266     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.98     Document Type: Review

References (103)

1. Kawakami Y, Eliyahu S, Delgado CH et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl Acad. Sci. USA 91(9), 3515-3519 (1994). (Pubitemid 24139460)
2. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038), 1643-1647 (1991). (Pubitemid 21917508)
3. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 54(3), 187-207 (2005). (Pubitemid 40174238)
4. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
5. Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat. Med. 9(5), 619-624 (2003). (Pubitemid 36597110)
6. Maus MV, Thomas AK, Leonard DG et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat. Biotechnol. 20(2), 143-148 (2002). (Pubitemid 34158029)
7. Durai M, Krueger C, Ye Z et al. In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). Cancer Immunol. Immunother. 58(2), 209-220 (2009).
8. Steenblock ER, Fahmy TM. A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. Mol. Ther. 16(4), 765-772 (2008). (Pubitemid 351426179)
9. Steenblock ER, Fadel T, Labowsky M, Pober JS, Fahmy TM. An artificial antigen-presenting cell with paracrine delivery of IL-2 impacts the magnitude and direction of the T cell response. J. Biol. Chem. 286(40), 34883-34892 (2011).
10. Engelhard VH, Strominger JL, Mescher M, Burakoff S. Induction of secondary cytotoxic T lymphocytes by purified HLA-A and HLA-B antigens reconstituted into phospholipid vesicles. Proc. Natl Acad. Sci. USA 75(11), 5688-5691 (1978). (Pubitemid 9101459)
11. Mescher MF. Surface contact requirements for activation of cytotoxic T lymphocytes. J. Immunol. 149(7), 2402-2405 (1992).
12. Curtsinger J, Deeths MJ, Pease P, Mescher MF. Artificial cell surface constructs for studying receptor-ligand contributions to lymphocyte activation. J. Immunol. Methods 209(1), 47-57 (1997). (Pubitemid 28032143)
13. Turtle CJ, Riddell SR. Artificial antigen-presenting cells for use in adoptive immunotherapy. Cancer J. 16(4), 374-381 (2010).
14. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38(5), 1404-1413 (2008).
15. Gilboa E. The makings of a tumor rejection antigen. Immunity 11(3), 263-270 (1999). (Pubitemid 29463234)
16. Jenkins MK, Taylor PS, Norton SD, Urdahl KB. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J. Immunol. 147(8), 2461-2466 (1991).
17. Curtsinger JM, Schmidt CS, Mondino A et al. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J. Immunol. 162(6), 3256-3262 (1999). (Pubitemid 29313572)
18. Grakoui A, Bromley SK, Sumen C et al. The immunological synapse: a molecular machine controlling T cell activation. Science 285(5425), 221-227 (1999). (Pubitemid 29329988)
19. Lee KH, Holdorf AD, Dustin ML, Chan AC, Allen PM, Shaw AS. T cell receptor signaling precedes immunological synapse formation. Science 295(5559), 1539-1542 (2002). (Pubitemid 34174012)
20. Rosenberg SA, Packard BS, Aebersold PM et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319(25), 1676-1680 (1988). (Pubitemid 19015247)
21. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594), 850-854 (2002). (Pubitemid 35231542)
22. Kurokawa T, Oelke M, Mackensen A. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. Int. J. Cancer 91(6), 749-756 (2001). (Pubitemid 32178640)
23. Altman JD, Moss PA, Goulder PJ et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274(5284), 94-96 (1996). (Pubitemid 26332731)
24. Neudorfer J, Schmidt B, Huster KM et al. Reversible HLA multimers (streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor-and virus-derived antigens. J. Immunol. Methods 320(1-2), 119-131 (2007). (Pubitemid 46349106)
25. Nguyen DN, Green JJ, Chan JM, Longer R, Anderson DG. Polymeric materials for gene delivery and dna vaccination. Adv. Mater. 21(8), 847-867 (2009).
26. Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci. Transl. Med. 4(127), 127ps8 (2012).
27. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796), 126-129 (2006). (Pubitemid 44547756)
28. Giannoni F, Barnett J, Bi K et al. Clustering of T cell ligands on artificial APC membranes influences T cell activation and protein kinase C theta translocation to the T cell plasma membrane. J. Immunol. 174(6), 3204-3211 (2005). (Pubitemid 40354022)
29. Ugel S, Zoso A, De Santo C et al. In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Cancer Res. 69(24), 9376-9384 (2009).
30. Levine BL, Bernstein WB, Connors M et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J. Immunol. 159(12), 5921-5930 (1997). (Pubitemid 127471527)
31. Maus MV, Riley JL, Kwok WW, Nepom GT, June CH. HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells. Clin. Immunol. 106(1), 16-22 (2003). (Pubitemid 36263297)
32. Han H, Peng JR, Chen PC et al. A novel system of artificial antigen-presenting cells efficiently stimulates Flu peptide-specific cytotoxic T cells in vitro. Biochem. Biophys. Res. Commun. 411(3), 530-535 (2011).
33. Haveman LM, Bierings M, Klein MR et al. Selection of perforin expressing CD4+ adenovirus-specific T-cells with artificial antigen-presenting cells. Clin. Immunol. 146(3), 228-239 (2013).
34. Schutz C, Fleck M, Mackensen A et al. Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells. Blood 111(7), 3546-3552 (2008).
35. Schutz C, Oelke M, Schneck JP, Mackensen A, Fleck M. Killer artificial antigen-presenting cells: the synthetic embodiment of a 'guided missile'. Immunotherapy 2(4), 539-550 (2010).
36. Webb TJ, Bieler JG, Schneck JP, Oelke M. Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen-presenting cells. J. Immunol. Methods 346(1-2), 38-44 (2009).
37. Sun W, Subrahmanyam PB, East JE, Webb TJ. Connecting the dots: artificial antigen-presenting cell-mediated modulation of natural killer T cells. J. Interferon Cytokine Res. 32(11), 505-516 (2012).
38. Shiratsuchi T, Schneck J, Kawamura A, Tsuji M. Human CD1 dimeric proteins as indispensable tools for research on CD1-binding lipids and CD1-restricted T cells. J. Immunol. Methods 345(1-2), 49-59 (2009).
39. Sauer MG, Ericson ME, Weigel BJ et al. A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells. Cancer Res. 64(11), 3914-3921 (2004). (Pubitemid 38697304)
40. O'Herrin SM, Slansky JE, Tang Q et al. Antigen-specific blockade of T cells in vivo using dimeric MHC peptide. J. Immunol. 167(5), 2555-2560 (2001). (Pubitemid 32768882)
41. Pareja E, Tobes R, Martin J, Nieto A. The tetramer model: a new view of class II MHC molecules in antigenic presentation to T cells. Tissue Antigens 50(5), 421-428 (1997). (Pubitemid 27458263)
42. Deeths MJ, Mescher MF. B7-1-dependent co-stimulation results in qualitatively and quantitatively different responses by CD4+ and CD8+ T cells. Eur. J. Immunol. 27(3), 598-608 (1997). (Pubitemid 27110570)
43. Deeths MJ, Mescher MF. ICAM-1 and B7-1 provide similar but distinct costimulation for CD8+ T cells, while CD4+ T cells are poorly costimulated by ICAM-1. Eur. J. Immunol. 29(1), 45-53 (1999). (Pubitemid 29043521)
44. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27(1), 111-122 (2007). (Pubitemid 47089023)
45. Ndhlovu ZM, Oelke M, Schneck JP, Griffin DE. Dynamic regulation of functionally distinct virus-specific T cells. Proc. Natl Acad. Sci. USA 107(8), 3669-3674 (2010).
46. Fuertes Marraco SA, Baumgaertner P, Legat A, Rufer N, Speiser DE. A stepwise protocol to coat aAPC beads prevents out-competition of anti-CD3 mAb and consequent experimental artefacts. J. Immunol. Methods 385(1-2), 90-95 (2012).
47. Shalaby WS, Yeh H, Woo E et al. Absorbable microparticulate cation exchanger for immunotherapeutic delivery. J. Biomed. Mater. Res. B Appl. Biomater. 69(2), 173-182 (2004). (Pubitemid 38619775)
48. Fahmy TM, Samstein RM, Harness CC, Mark Saltzman W. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials 26(28), 5727-5736 (2005). (Pubitemid 40616843)
49. Pawar AB, Kretzschmar I. Fabrication, assembly, and application of patchy particles. Macromol. Rapid Commun. 31(2), 150-168 (2010).
50. Walther A, Muller AHE. Janus particles. Soft Matter 4(4), 663-668 (2008). (Pubitemid 351434073)
51. Doh J, Irvine DJ. Immunological synapse arrays: patterned protein surfaces that modulate immunological synapse structure formation in T cells. Proc. Natl Acad. Sci. USA 103(15), 5700-5705 (2006).
52. Snyder CE, Yake AM, Feick JD, Velegol D. Nanoscale functionalization and site-specific assembly of colloids by particle lithography. Langmuir 21(11), 4813-4815 (2005). (Pubitemid 40795300)
53. Cayre O, Paunov VN, Velev OD. Fabrication of dipolar colloid particles by microcontact printing. Chem. Commun, Camb.18, 2296-2297 (2003). (Pubitemid 37163946)
54. Cayre O, Paunov VN, Velev OD. Fabrication of asymmetrically coated colloid particles by microcontact printing techniques. J. Mater. Chem. 13(10), 2445-2450 (2003).
55. Zhao YP, Ye DX, Wang GC, Lu TM. Novel nano-column and nano-flower arrays by glancing angle deposition. Nano Lett. 2(4), 351-354 (2002).
56. Pawar AB, Kretzschmar I. Multifunctional patchy particles by glancing angle deposition. Langmuir 25(16), 9057-9063 (2009).
57. Zhang G, Wang DY, Mohwald H. Patterning microsphere surfaces by templating colloidal crystals. Nano Lett. 5(1), 143-146 (2005). (Pubitemid 40168917)
58. Kamalasanan K, Jhunjhunwala S, Wu J, Swanson A, Gao D, Little SR. Patchy, anisotropic microspheres with soft protein islets. Angew. Chem. Int. Ed. Engl. 50(37), 8706-8708 (2011).
59. Serra CA, Chang ZQ. Microfluidic-assisted synthesis of polymer particles. Chem. Eng. Technol. 31(8), 1099-1115 (2008).
60. Nie ZH, Li W, Seo M, Xu SQ, Kumacheva E. Janus and ternary particles generated by microfluidic synthesis: design, synthesis, and self-assembly. J. Am. Chem. Soc. 128(29), 9408-9412 (2006). (Pubitemid 44117099)
61. Roh KH, Martin DC, Lahann J. Biphasic Janus particles with nanoscale anisotropy. Nat. Mater. 4(10), 759-763 (2005). (Pubitemid 41397023)
62. Mossman KD, Campi G, Groves JT, Dustin ML. Altered TCR signaling from geometrically repatterned immunological synapses. Science 310(5751), 1191-1193 (2005). (Pubitemid 41681746)
63. Pike LJ. Rafts defined: a report on the Keystone Symposium on Lipid Rafts and Cell Function. J. Lipid. Res. 47(7), 1597-1598 (2006). (Pubitemid 44079915)
64. Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. Science 327(5961), 46-50 (2010).
65. Hancock JF. Lipid rafts: contentious only from simplistic standpoints. Nat. Rev. Mol. Cell Biol. 7(6), 456-462 (2006). (Pubitemid 44050099)
66. Nicolau DV, Burrage K, Parton RG, Hancock JF. Identifying optimal lipid raft characteristics required to promote nanoscale protein-protein interactions on the plasma membrane. Mol. Cell. Biol. 26(1), 313-323 (2006).
67. Vogt AB, Spindeldreher S, Kropshofer H. Clustering of MHC-peptide complexes prior to their engagement in the immunological synapse: lipid raft and tetraspan microdomains. Immunol. Rev. 189, 136-151 (2002) (Pubitemid 35448949)
68. Anderson HA, Hiltbold EM, Roche PA. Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation. Nat. Immunol. 1(2), 156-162 (2000).
69. Zappasodi R, Di Nicola M, Carlo-Stella C et al. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells. Haematologica 93(10), 1523-1534 (2008).
70. Tan S, Li X, Guo Y, Zhang Z. Lipid-enveloped hybrid nanoparticles for drug delivery. Nanoscale 5(3), 860-872 (2013).
71. Mossman KD, Campi G, Groves JT, Dustin ML. Altered TCR signaling from geometrically repatterned immunological synapses. Science 310(5751), 1191-1193 (2005). (Pubitemid 41681746)
72. Jin T, Pennefather P, Lee PI. Lipobeads: a hydrogel anchored lipid vesicle system. FEBS Lett. 397(1), 70-74 (1996). (Pubitemid 26380176)
73. Liu J, Jiang X, Ashley C, Brinker CJ. Electrostatically mediated liposome fusion and lipid exchange with a nanoparticle-supported bilayer for control of surface charge, drug containment, and delivery. J. Am. Chem. Soc. 131(22), 7567-7569 (2009).
74. Mornet S, Lambert O, Duguet E, Brisson A. The formation of supported lipid bilayers on silica nanoparticles revealed by cryoelectron microscopy. Nano Lett. 5(2), 281-285 (2005). (Pubitemid 40308285)
75. Hu CM, Zhang L, Aryal S, Cheung C, Fang RH. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl Acad. Sci. USA 108(27), 10980-10985 (2011).
76. Ashley CE, Carnes EC, Phillips GK et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat. Mater. 10(5), 389-397 (2011).
77. Porotto M, Yi F, Moscona A, LaVan DA. Synthetic protocells interact with viral nanomachinery and inactivate pathogenic human virus. PLoS One 6, 3 e16874(2011).
78. Parodi A, Quattrocchi N, van de Ven AL et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat. Nanotechnol. 8(1), 61-68 (2013).
79. Fletcher DA, Mullins RD. Cell mechanics and the cytoskeleton. Nature 463(7280), 485-492 (2010).
80. Merkel TJ, Herlihy KP, Nunes J, Orgel RM, Rolland JP, DeSimone JM. Scalable, shape-specific, top-down fabrication methods for the synthesis of engineered colloidal particles. Langmuir 26(16), 13086-13096 (2010).
81. Glotzer SC, Solomon MJ. Anisotropy of building blocks and their assembly into complex structures. Nat. Mater. 6(8), 557-562 (2007). (Pubitemid 47197675)
82. Merkel TJ, Jones SW, Herlihy KP et al. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc. Natl Acad. Sci. USA 108(2), 586-591 (2011).
83. Champion JA, Katare YK, Mitragotri S. Particle shape: a new design parameter for micro-and nanoscale drug delivery carriers. J. Control. Release 121(1-2), 3-9 (2007). (Pubitemid 47126059)
84. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc. Natl Acad. Sci. USA 103(13), 4930-4934 (2006).
85. Champion JA, Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharm. Res. 26(1), 244-249 (2009).
86. Sharma G, Valenta DT, Altman Y et al. Polymer particle shape independently influences binding and internalization by macrophages. J. Control. Release 147(3), 408-412 (2010).
87. Muro S, Garnacho C, Champion JA et al. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol. Ther. 16(8), 1450-1458 (2008).
88. Geng Y, Dalhaimer P, Cai S et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2(4), 249-255(2007). (Pubitemid 46739812)
89. Barua S, Yoo JW, Kolhar P, Wakankar A, Gokarn YR, Mitragotri S. Particle shape enhances specificity of antibody-displaying nanoparticles. Proc. Natl Acad. Sci. USA 110(9), 3270-3275 (2013).
90. Fadel TR, Steenblock ER, Stern E et al. Enhanced cellular activation with single walled carbon nanotube bundles presenting antibody stimuli. Nano Lett. 8(7), 2070-2076 (2008).
91. Fadel TR, Look M, Staffier PA, Haller GL, Pfefferle LD, Fahmy TM. Clustering of stimuli on single-walled carbon nanotube bundles enhances cellular activation. Langmuir 26(8), 5645-5654 (2010).
92. Ho CC, Keller A, Odell JA, Ottewill RH. Preparation of monodisperse ellipsoidal polystyrene particles. Colloid Polym. Sci. 271(5), 469-479 (1993). (Pubitemid 23682994)
93. Champion JA, Katare YK, Mitragotri S. Making polymeric micro-and nanoparticles of complex shapes. Proc. Natl Acad. Sci. USA 104(29), 11901-11904 (2007). (Pubitemid 47185602)
94. Yoo JW, Mitragotri S. Polymer particles that switch shape in response to a stimulus. Proc. Natl Acad. Sci. USA 107(25), 11205-11210 (2010).
95. Sunshine JC, Perica K, Schneck JP, Green JJ. Non-spherical artificial antigen presenting cells for tumor immunotherapy. Presented at: Society For Biomaterials Annual Meeting 2013. Boston, MA, USA, 10-13 April 2013.
96. Rolland JP, Maynor BW, Euliss LE, Exner AE, Denison GM, DeSimone JM. Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. J. Am. Chem. Soc. 127(28), 10096-10100 (2005). (Pubitemid 40995455)
97. Kelly JY, DeSimone JM. Shape-specific, monodisperse nano-molding of protein particles. J. Am. Chem. Soc. 130(16), 5438-5439 (2008). (Pubitemid 351612948)
98. Wang Y, Merkel TJ, Chen K, Fromen CA, Betts DE, DeSimone JM. Generation of a library of particles having controlled sizes and shapes via the mechanical elongation of master templates. Langmuir 27(2), 524-528 (2011).
99. Dendukuri D, Pregibon DC, Collins J, Hatton TA, Doyle PS. Continuous-flow lithography for high-throughput microparticle synthesis. Nat. Mater. 5(5), 365-369 (2006).
100. Yu Y, Ai B, Mohwald H, Zhou ZW, Zhang G, Yang B. Fabrication of binary and ternary hybrid particles based on colloidal lithography. Chem. Mater. 24(23), 4549-4555 (2012).
101. Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 440(7086), 890-895 (2006).
102. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392(6673), 245-252 (1998). (Pubitemid 28155090)
103. Dustin ML, Groves JT. Receptor signaling clusters in the immune synapse. Annu. Rev. Biophys. 41, 543-556 (2012).